What is Microdermics?
Microdermics is at the forefront of transforming drug delivery for the biopharmaceutical sector and patients worldwide. The company has developed a proprietary microneedle injection system designed to replace traditional hypodermic needles, addressing a critical need within the vast $800 billion global biotherapeutics market. Their scalable, customizable, and versatile microneedle platform is engineered to enhance patient comfort and optimize drug delivery efficiency, targeting biopharma companies and patients seeking advanced administration solutions.
How much funding has Microdermics raised?
Microdermics has raised a total of $1M across 1 funding round:
Unspecified
$1M
Unspecified (2017): $1M with participation from K5 Ventures and Shoreline Ventures
Key Investors in Microdermics
K5 Ventures
K5 Ventures is an early-stage venture capital fund based in California, known for backing game-changing innovations and exceptional teams, with a particular interest in AI-driven solutions.
Shoreline Ventures
Shoreline Ventures is a venture capital firm specializing in early-stage tech startups, with a focus on enterprise software, healthcare IT, and big data analytics, providing operational guidance and access to capital.
What's next for Microdermics?
With the recent major strategic investment and substantial overall funding, Microdermics is well-positioned for significant expansion and market penetration. This capital injection is expected to accelerate the development and commercialization of their innovative microneedle technology, potentially enabling broader adoption across various therapeutic areas. The company's focus on patient comfort and improved drug delivery efficiency aligns with key trends in the biopharmaceutical industry, suggesting a strategic path toward scaling operations and solidifying its market presence.
See full Microdermics company page
